科兴制药：靶向创新药GB19注射液获临床试验批准

Core Viewpoint - The article reports that Sinovac Biotech has received approval from the National Medical Products Administration for clinical trials of its innovative drug "GB19 injection," which targets BDCA2 (blood dendritic cell antigen 2) [1] Group 1 - Sinovac's wholly-owned subsidiary, Shenzhen Sinovac Biotech Co., Ltd., has been granted a Clinical Trial Approval Notification by the National Medical Products Administration [1] - The approved drug, "GB19 injection," is an innovative medication developed independently by Shenzhen Sinovac [1]